Response To Rituximab, Cyclophosphamide And Dexamethasone As Initial Or Salvage Therapy In Low Grade Lymphoma And Immune Hemolytic Anemia.

BACKGROUND: The combination of dexamethasone, cyclophosphamide, and rituximab (RCD) have documented activity in lymphoproliferative disorders without severe side effects and shows significant results in the setting of AIHA (auto immune hemolytic anemia) in CLL (chronic lymphocytic leukemia). We conducted a retrospective study of the response to RCD in low grade lymphoproliferative disorders and in AIHA at our institution.